Table of Content

1. PREFACE
1.1. DNA Encoded Library Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development
3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Validation
3.3.3. Hit Generation
3.3.3.1. High-throughput Screening
3.3.3.2. Fragment-based Screening
3.3.3.3. Virtual Screening
3.3.3.4. DNA Encoded Library Screening
3.3.4. Lead Generation
3.3.5. Lead Optimization
3.4. Overview of DNA Encoded Libraries
3.4.1. Encoding Strategies for Library Construction
3.4.2. Historical Evolution of DNA Encoded Libraries
3.4.3. Comparison of Traditional Libraries and DNA Encoded Libraries
3.4.4. Key Advantages of DNA Encoded Libraries
3.4.5. Challenges and Limitations Associated with DNA Encoded Libraries
3.5. Future Perspectives and Opportunity Areas

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. DNA Encoded Library: Overall Market Landscape of Service Providers / Platform Providers / In-House Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Company / Organization
4.2.6. Analysis by Library Size
4.2.7. Analysis by Library Synthesis Method(s)
4.2.8. Analysis by Library Screening Method(s)
4.2.9. Analysis by Type of Product(s) Offered
4.2.10. Analysis by Type of Service(s) Offered
4.2.10.1. Analysis by Type of Library Design Service(s) Offered
4.2.10.2. Analysis by Type of Library Screening Service(s) Offered
4.2.11. Analysis by Type of Pharmacological Lead(s)
4.2.12. Analysis by Therapeutic Target(s)
4.2.13. Analysis by Therapeutic Area(s)
4.2.14. Analysis by End-user(s)

5. BUSINESS MODEL ANALYSIS
5.1. Chapter Overview
5.2. DNA Encoded Library Companies: Business Model Analysis
5.2.1. Analysis by Operational Model
5.2.1.1. Analysis by Company Size and Operational Model
5.2.1.2. Analysis by Location of Headquarters and Operational Model
5.2.2. Analysis by Business Model
5.2.2.1. Analysis by Service Centric Model
5.2.2.2. Analysis by Product Centric Model
5.3. Concluding Remarks

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: DNA Encoded Library Service Providers / Platform Providers / In-House Companies
6.4.1. DNA Encoded Library Companies based in North America
6.4.2. DNA Encoded Library Companies based in Europe
6.4.3. DNA Encoded Library Companies based in Asia-Pacific

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. AlphaMa
7.2.1. Company Overview
7.2.2. DNA Encoded Library Platform and Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. DICE Therapeutics
7.3.1. Company Overview
7.3.2. DNA Encoded Library Platform and Service Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. DyNAbind
7.4.1. Company Overview
7.4.2. DNA Encoded Library Platform and Service Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. HitGen
7.5.1. Company Overview
7.5.2. DNA Encoded Library Platform and Service Portfolio
7.5.3. Recent Developments and Future Outlook
7.6. NovAliX
7.6.1. Company Overview
7.6.2. DNA Encoded Library Platform and Service Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Vipergen
7.7.1. Company Overview
7.7.2. DNA Encoded Library Platform and Service Portfolio
7.7.3. Recent Developments and Future Outlook
7.8. WuXi AppTec
7.8.1. Company Overview
7.8.2. DNA Encoded Library Platform and Service Portfolio
7.8.3. Recent Developments and Future Outlook
7.9. X-Chem
7.9.1. Company Overview
7.9.2. DNA Encoded Library Platform and Service Portfolio
7.9.3. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. DNA Encoded Libraries: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Focus Area
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Type of Partner
8.3.6.1 Analysis by Partner Company Size
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Analysis by Geography
8.3.8.1. International and Local Agreements
8.3.8.2. Intercontinental and Intracontinental Agreements

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. DNA Encoded Libraries: Funding and Investment Analysis
9.3.1. Analysis of Instances by Year of Funding
9.3.2. Analysis of Amount Invested by Year of Funding
9.3.3. Analysis of Instances by Type of Funding
9.3.4. Analysis of Amount Invested by Type of Funding
9.3.5. Most Active Players: Analysis by Number of Funding Instances
9.3.6. Most Active Players: Analysis by Amount Raised
9.3.7. Most Active Investors: Analysis by Number of Instances
9.3.8. Analysis by Geography
9.3.9. Concluding Remarks

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. DNA Encoded Libraries: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis by Patent Application Year
10.3.3. Analysis by Type of Patent and Publication Year
10.3.4. Analysis by Patent Jurisdiction
10.3.5. Analysis by CPC Symbols
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Industry Players: Analysis by Number of Patents
10.3.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3.9. Leading Individual Assignees: Analysis by Number of Patents
10.4. DNA Encoded Libraries: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. DNA Encoded Libraries: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations

11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. DNA Encoded Libraries Related Initiatives of Big Pharma Players
11.4. Benchmark Analysis of Big Pharma Players
11.4.1. Spider Web Analysis: AbbVie
11.4.2. Spider Web Analysis: Amgen
11.4.3. Spider Web Analysis: AstraZeneca
11.4.4. Spider Web Analysis: Bayer
11.4.5. Spider Web Analysis: Boehringer Ingelheim
11.4.6. Spider Web Analysis: Eli Lilly
11.4.7. Spider Web Analysis: GlaxoSmithKline (GSK)
11.4.8. Spider Web Analysis: Johnson & Johnson
11.4.9. Spider Web Analysis: Merck
11.4.10. Spider Web Analysis: Novartis
11.4.11. Spider Web Analysis: Pfizer
11.4.12. Spider Web Analysis: Sanofi
11.5. Concluding Remarks
12. CASE STUDY: COMPANIES / ORGANIZATIONS SUPPORTING THE DEVELOPMENT OF DNA ENCODED LIBRARIES
12.1. Chapter Overview
12.2. DNA Encoded Libraries: Overall Market Landscape of Supporting Companies / Organizations
12.2.1. Analysis by Year of Establishment
12.2.2. Analysis by Company Size
12.2.3. Analysis by Location of Headquarters
12.2.4. Analysis by Company Size and Location of Headquarters
12.2.5. Analysis by Type of Company / Organization
12.2.6. Analysis by Type of Support Services / Ancillary Tools Offered
12.2.7. Analysis by Location of Headquarters and Type of Support Services / Ancillary Tools Offered
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Scenario, 2017-2035
13.3.1. DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035
13.3.1.1. DNA Encoded Library Market for Hit Generation / Identification, 2023-2035
13.3.1.2. DNA Encoded Library Market for Hit to Lead, 2023-2035
13.3.1.3. DNA Encoded Library Market for Hit Validation / Optimization, 2023-2035
13.3.1.4. DNA Encoded Library Market for Other Application Areas, 2023-2035
13.3.2. DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035
13.3.2.1. DNA Encoded Library Market for Oncological Disorders, 2023-2035
13.3.2.2. DNA Encoded Library Market for Immunological Disorders, 2023-2035
13.3.2.3. DNA Encoded Library Market for Neurological Disorders, 2023-2035
13.3.2.4. DNA Encoded Library Market for Respiratory Disorders, 2023-2035
13.3.2.5. DNA Encoded Library Market for Dermatological Disorders, 2023-2035
13.3.2.6. DNA Encoded Library Market for Cardiovascular Disorders, 2023-2035
13.3.2.7. DNA Encoded Library Market for Infectious Diseases, 2023-2035
13.3.2.8. DNA Encoded Library Market for Other Therapeutic Areas, 2023-2035
13.3.3. DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035
13.3.3.1. DNA Encoded Library Market for Pharma / Biopharma Industry, 2023-2035
13.3.3.2. DNA Encoded Library Market for Academic / Research Institute, 2023-2035
13.3.3.3. DNA Encoded Library Market for Other End-users, 2023-2035
13.3.4. DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035
13.3.4.1. DNA Encoded Library Market: Upfront Payments, 2023-2035
13.3.4.2. DNA Encoded Library Market: Milestone Payments, 2023-2035
13.3.5. DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035
13.3.5.1. DNA Encoded Library Market in North America, 2023-2035
13.3.5.1.1. DNA Encoded Library Market in the US, 2023-2035
13.3.5.2. DNA Encoded Library Market in Europe, 2023-2035
13.3.5.2.1. DNA Encoded Library Market in Denmark, 2023-2035
13.3.5.2.2. DNA Encoded Library Market in Germany, 2023-2035
13.3.5.2.3. DNA Encoded Library Market in the UK, 2023-2035
13.3.5.2.4. DNA Encoded Library Market in Switzerland, 2023-2035
13.3.5.2.5. DNA Encoded Library Market in France, 2023-2035
13.3.5.2.6. DNA Encoded Library Market in Rest of the Europe, 2023-2035
13.3.5.3. DNA Encoded Library Market in Asia-Pacific, 2023-2035
13.3.5.3.1. DNA Encoded Library Market in China, 2023-2035

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Vipergen
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Nils Jakob Vest Hansen, Chief Executive Officer
15.3. Serengen
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Thorsten Genski, Chief Executive Officer
15.4. Deluge Biotechnologies
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Thomas Kodadek, Co-Founder and Ofelia Utset, President
15.5. NovAliX
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Frank Moffatt, Director of Business Development
15.6. Orbit Discovery
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Christos Tsiamantas, Senior Scientist
15.7. Anonymous

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS